COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 06/30/2024 | 06/30/2024 | 03/31/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.50% | -1.50% | -118.85% | 75.14% | 279.30% |
| Total Depreciation and Amortization | 5.01% | 5.01% | -72.74% | 734.88% | 3,035.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -443.22% | -443.22% | 64.01% | -92.27% | -236.04% |
| Change in Net Operating Assets | 289.18% | 289.18% | -163.52% | -329.36% | 1,709.57% |
| Cash from Operations | 42.15% | 42.15% | -126.22% | 55.37% | 370.57% |
| Capital Expenditure | 72.16% | 72.16% | 20.34% | -11,180.00% | -7,766.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -600.00% |
| Cash from Investing | 4,688.65% | 4,688.65% | 21.12% | -203.87% | -7,050.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -75.00% | -75.00% | 71.98% | -89.47% | -678.79% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -75.00% | -75.00% | 70.49% | -89.47% | -639.39% |
| Foreign Exchange rate Adjustments | 50.37% | 50.37% | -192.47% | -200.00% | 4,966.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 866.02% | 866.02% | -138.02% | 33.08% | 343.24% |